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Abstract
Background: Clinical inertia has been defined as mistakes by the physician in starting or intensifying treatment when
indicated. Inertia, therefore, can affect other stages in the healthcare process, like diagnosis. The diagnosis of dyslipidemia
requires$2 high lipid values, but inappropriate behavior in the diagnosis of dyslipidemia has only previously been analyzed
using just total cholesterol (TC).
Objectives: To determine clinical inertia in the dyslipidemia diagnosis using both TC and high-density lipoprotein
cholesterol (HDL-c) and its associated factors.
Design: Cross-sectional.
Setting: All health center visits in the second half of 2010 in the Valencian Community (Spain).
Patients: 11,386 nondyslipidemic individuals aged $20 years with $2 lipid determinations.
Measurement Variables: Gender, atrial fibrillation, hypertension, diabetes, cardiovascular disease, age, and ESCARVAL
training course. Lipid groups: normal (TC,5.17 mmol/L and normal HDL-c [$1.03 mmol/L in men and $1.29 mmol/L in
women], TC inertia (TC$5.17 mmol/L and normal HDL-c), HDL-c inertia (TC,5.17 mmol/L and low HDL-c), and combined
inertia (TC$5.17 mmol/L and low HDL-c).
Results: TC inertia: 38.0% (95% CI: 37.2–38.9%); HDL-c inertia: 17.7% (95% CI: 17.0–18.4%); and combined inertia: 9.6% (95%
CI: 9.1–10.2%). The profile associated with TC inertia was: female, no cardiovascular risk factors, no cardiovascular disease,
middle or advanced age; for HDL-c inertia: female, cardiovascular risk factors and cardiovascular disease; and for combined
inertia: female, hypertension and middle age.
Limitations: Cross-sectional study, under-reporting, no analysis of some cardiovascular risk factors or other lipid parameters.
Conclusions: A more proactive attitude should be adopted, focusing on the full diagnosis of dyslipidemia in clinical practice.
Special emphasis should be placed on patients with low HDL-c levels and an increased cardiovascular risk.
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Introduction
Dyslipidemia is one of the main risk factors for ischemic heart
disease, which is the leading cause of death worldwide [1–5].
Thus, early screening for detection of dyslipidemia is a key element
when attempting to prevent the complications of coronary disease.
The main scientific societies recommend screening for dyslipide-
mia in adults [6,7]. In Spain, the 2007 preventive activities
program of the Spanish Society of Family and Community
Medicine [8] only indicated in the screening process the
measurement of total cholesterol (TC), whilst the 2009 program
[9] recommended adding high-density lipoprotein cholesterol
(HDL-c) to quantify the cardiovascular risk. Once the physician
makes a diagnosis of dyslipidemia he or she should then take the
appropriate action according to the relevant guidelines. This
action may concern various possibilities, including dietary and
hygiene measures or pharmacologic treatment [6,8,9].
Phillips et al [10] defined clinical inertia as mistakes by the
physician in starting or intensifying treatment when indicated.
Later Andrade et al defined the concept of therapeutic inertia
[11]. The definition of these concepts means that inertia can affect
other stages in the healthcare process, like diagnosis. Other
authors have analyzed the inappropriate behavior of physicians in
the diagnosis of dyslipidemia using TC (Table 1), although they
did not call it clinical inertia. This behavior was assessed in several
ways: lack of monitoring or diagnosis when it was required,
unawareness of high blood cholesterol by the patient and not
considering high blood cholesterol as a problem. All these studies
involve a significant proportion of clinical inertia in the diagnosis
of dyslipidemia, especially considering that it is a disease that must
be controlled to reduce the incidence of coronary disease (Table 1).
The Valencian Community is a Mediterranean region in
eastern Spain with a population of 5,004,475 inhabitants (2010
figures) [24]. The health system has universal coverage and
primary care is freely accessible. There is a unique insurance
number for each patient and a unique electronic health record for
the whole Valencian population. In this population, TC is
abnormal in approximately 50% of patients and HDL-c in one
out of every four patients (NCEP criteria) [6,25,26]. Furthermore,
patients with low HDL-c levels have a higher proportion of
diabetes mellitus [26]. In Spain, the health costs of lipid-lowering
medication are around J971 million per year, equivalent to 1.5%
of total healthcare spending [27,28]. Drug therapy and lifestyle
modifications have a high level of cost-effectiveness in life-years
gained [29,30]. However, the noncompliance rate is around 40%
for lipid-lowering drugs and 70% for lifestyle modifications
[31,32].
The ESCARVAL study (EStudio CARdiometabo´lico VALen-
ciano) [33] was implemented in the Valencian Community, Spain.
A cross-sectional phase of this study estimated the degree of
awareness/unawareness for hypertension, dyslipidemia and dia-
betes, and the evolution over time of cardiovascular risk factors.
Another longitudinal cardiovascular phase generated predictive
scales in the general population and in patients diagnosed with
hypertension, dyslipidemia and diabetes by analyzing the
incidence of cardiovascular events and associated factors [33,34].
As part of the cross-sectional ESCARVAL objectives, by means
of the analysis of the electronic medical records, this present study
determined the clinical inertia in the diagnosis of dyslipidemia in
the population attending their health center along with the factors
associated with this problem. As a new feature that adds to the
work of other authors (Table 1), this study determines the clinical
inertia in diagnosis taking into account the two metabolic disorders
of TC and HDL-c. This resulted in determining different types of
inertia in the diagnosis of dyslipidemia. The need for measures to
improve the diagnosis of dyslipidemia can be seen from the results.
Materials and Methods
Study Population
The study population comprised all those persons who can
attend their health centers in the Valencian Community. The
typical profile of these persons is: mainly women, coexistence of
cardiovascular risk factors, older age, and frequent visitors [35].
Study Design and Participants
This observational, cross-sectional study analyzed a sample of
nondyslipidemic individuals aged 20 years or older who had
electronic medical records (Abucasis) and who attended their
health center in the Valencian Community at least once between
July and December 2010. We used this end time due to the delay
Abucasis has in deleting deceased patients. Thus, it was certain
that the information analyzed concerned patients who were alive.
A patient was considered to have dyslipidemia if he or she had
been diagnosed as such using ICD-9-CM codes (272.x). In
addition, each patient had to have two or more lipid determina-
tions (TC and HDL-c) in Abucasis in the second half of 2010.
With these data, the physician could confirm or exclude the
diagnosis of dyslipidemia, using both TC and HDL-c [8,9]. All
patients who did not meet these criteria were excluded.
Variables and Measurements
We studied the information registered in the clinical record
from when Abucasis began (May 2003) to December 2010. The
patient information extracted from Abucasis included gender, a
diagnosis of atrial fibrillation, hypertension or diabetes mellitus,
having had cardiovascular disease (defined according to the ESH/
ESC guidelines [36]), age group (20–44, 45–59, 60–74,$75 years)
(this grouping was based on a report from the WHO) [37] and
whether the physicians had done the online ESCARVAL
cardiovascular skills training course, offered voluntarily and free
of charge to all healthcare professionals in the Valencian
Community. This online course was done in one academic year
(2007–2008) and was composed of three modules: Cardiovascular
Clinical Skills (Module I), Lifestyle and Dietary Hygiene Measures
in the Prevention of Cardiovascular Disease (Module II), and
Cardiovascular Research Skills (Module III) [33].
In addition, we extracted the average values from July to
December 2010 of TC and HDL-c. According to these values,
patients were grouped into categories: normal (TC ,5.17 mmol/
L and normal HDL-c [$1.03 mmol/L in men and $1.29 mmol/
L in women] [25]) and diagnostic inertia. Diagnostic inertia was
defined as the patient having values of TC and/or HDL-c outside
the normal range but not being diagnosed with dyslipidemia
[6,25]. We defined three modes of diagnostic inertia: 1) TC
inertia: TC$5.17 mmol/L and normal HDL-c, 2) HDL-c inertia:
TC ,5.17 mmol/L and low HDL-c and 3) combined inertia: TC
$5.17 mmol/L and low HDL-c [6,25]. The choice of these
variables was the consensus of the ESCARVAL Steering
Committee. These variables are related to cardiovascular diseases.
Obesity was not analyzed due to under-reporting in Abucasis.
Sample Size
The sample size comprised 11,386 individuals who had no
diagnosis of dyslipidemia in their electronic medical records. Thus,
using a 95% confidence level and a maximum expected ratio
(p = q = 0.5) the expected error rate in the prevalence estimation of
each of the lipid categories was 0.92%.
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Statistical Analyses
Absolute and relative frequencies were used to describe the
variables. Multivariable logistic regression models were performed
to estimate the adjusted odds ratios (ORs) for the relationships
between diagnostic inertia categories and the study variables
(gender, diagnosis, age and the ESCARVAL course). Each of the
diagnostic inertia categories was compared with the group of
patients without inertia (normal TC and normal HDL-c). We
adjusted the ORs using all the patient characteristics (gender,
atrial fibrillation, hypertension, diabetes mellitus, cardiovascular
disease and age group) and whether the physician had or had not
done the on-line ESCARVAL course. The likelihood ratio test was
carried out for the goodness-of-fit of the models. All analyses were
performed at a 5% significance level and associated confidence
intervals (CI) were estimated for each relevant parameter. All the
analyses were performed using IBM SPSS Statistics 19.
Missing Data
No data were missing because all the diagnoses were extracted.
If the patient had no diagnosis in Abucasis, we considered that the
associated variable had a negative value (no diagnosis). In
addition, the ESCARVAL study has a record of all the physicians
who have completed the on-line course and their patients. Finally,
to formalize the clinical history of each patient it was essential to
record the gender and date of birth, so there was no possibility of
missing data.
Ethical Consideration
This study was approved by the Valencian Community Public
Health Ethics Committee. To comply with data protection
regulations the data required for the study were requested and
delivered by the principal investigator (Vicente F Gil-Guille´n) to
those responsible for their care. These data were supplied in
unbundled, anonymized, compressed and encrypted files using a
good privacy code and a cryptographic identification card of the
Table 1. Main characteristics of the studies that evaluate clinical inertia in the diagnosis of dyslipidemia.
Authors Population N Assessment of inertia Inertia
Factors
associated
Bell MM
et al [12]
Adults with TC$
6.20 mmol/L and
unknown dyslipidemia
93 Not diagnosing dyslipidemia 34% TC,7.76 mmol/L
and age$70 years
Centers for Disease
Control and Prevention
(CDC) [13]
Adults with high
blood cholesterol
8,112 Having high blood cholesterol
without patient awareness
36.7% Younger age, women
and race (blacks and
Mexican Americans)
Hudson JW
et al [14]
Adults with TC$
5.17 mmol/L
394{ Not taking any action 53%
Hyman DJ
et al [15]
Primary care physicians 119 Not taking any action in patients
without cardiovascular risk factors
and TC$5.17 mmol/L
23.7%*
Landzberg
JS et al [16]
Adults with TC$
6.85 mmol/L and
unknown dyslipidemia
99 Not being treated 78%
Levin SJ
et al [17]
Adults with TC$
6.20 mmol/L and
unknown dyslipidemia
192 Not taking any action 80%
Merkin SS
et al [18]
Adults with
high cholesterol
2,883 Having high blood cholesterol
without patient awareness
47.6% Higher educational level
and race (blacks and
Mexican Americans)
Naumburg EH
et al [19]
Adults with TC$
6.20 mmol/L
493 Not diagnosing dyslipidemia Minority races
Saturno Herna´ndez
PJ et al [20]
Adults with high blood
cholesterol
($2 lipid determinations)
500 Not diagnosing dyslipidemia 88.4% Towns.50,000 people
and doctors without
postgraduate education
Steinhagen-
Thiessen E et al [21]
Adults with known and
unknown dyslipidemia
35,551 Not diagnosing dyslipidemia
when the patients meet
criteria
56.7%* Younger age, female,
no DM, no hypertension,
no abdominal or central obesity,
no smoking, limited physical
exercise, unbalanced diet,
no CVD, no other
diseases (liver, rheumatism,
arthritis or dyspnea)
and higher educational
level
Stockbridge
H et al [22]
Adults with TC$
5.17 mmol/L
568 Not taking any action 17.1%*
Whiteside
C et al [23]
Adults with TC$
5.17 mmol/L
110 Not recognizing the high TC
as a problem
71%
Abbreviations: TC, total cholesterol; DM, diabetes mellitus; CVD, cardiovascular disease. *: This value was obtained through a weighted average. {: The sample size is not
given in the original article. We therefore obtained it from linear programming mathematical calculations based on the Simplex method.
doi:10.1371/journal.pone.0091567.t001
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principal investigator as an encryption key. Only the principal
investigator was able to access their content. Once decrypted,
computer processing was performed with the Foundation for the
Promotion of Health and Biomedical Research of Valencia
(FISABIO) being the sole custodian of this information. This
procedure guarantees the confidentiality of the data submitted to
comply with current legislation.
This population-based, non-interventional study (data from the
Valencian Community) used data from medical records and
informed consent was not required for included patients. The
researchers informed the Valencian Community Public Health
Ethics Committee about this omission (to locate the patients was
impracticable). The ethics committee approved this consent
procedure. This committee ensured that information access was
restricted, it did not compromise the interests or welfare of any
patient, it minimized the risk of injury and its use was in line with
current legislation.
Results
In Figure 1 we show the number of patients in each study phase.
Of a total of 1,395,669 patients who attended their health centers
during the second semester of 2010, 672,065 had known
dyslipidemia (48.2%, 95% CI: 48.1–48.2%) and were therefore
excluded from this study. Of the remaining patients, 11,386 (1.6%)
had at least two lipid profile determinations and thus entered this
study. The distribution of the lipid profile groups was: 3,946
patients had no inertia (34.7%, 95% CI: 33.8–35.5%), 4,332 had
TC inertia (38.0%, 95% CI: 37.2–38.9%), 2,013 had HDL-c
inertia (17.7%, 95% CI: 17.0–18.4%) and 1,095 had combined
inertia (9.6%, 95% CI: 9.1–10.2%).
Table 2 provides a summary of the main descriptive charac-
teristics of the study sample. There was a higher proportion of
women, a high prevalence of cardiovascular risk factors, and 7% of
the participants had cardiovascular disease. The largest age group
was the youngest (26.9%), and the physicians of 15.4% of the
patients had done the online course. The predominance of
women, and the high prevalence of cardiovascular risk factors and
cardiovascular disease was present in all lipid profile categories,
although there were variations in the percentages in each of the
categories. In all subgroups, the percentage of physicians who did
the on-line course was approximately 15%. Regarding age groups,
there was wide variability in all the subgroups analyzed.
Table 3 summarizes the analysis of factors (gender, diagnosis,
age and the ESCARVAL course) associated with each inertia
group. To determine these factors we calculated the ORs, adjusted
for all the patient characteristics (gender, atrial fibrillation,
hypertension, diabetes mellitus, cardiovascular disease and age
group) and whether the physician had or had not done the on-line
ESCARVAL course. The profile of variables significantly associ-
ated (p,0.05) with TC inertia was: female (OR = 0.64, 95% CI:
0.58–0.70), no atrial fibrillation (OR = 0.59, 95% CI: 0.45–0.77),
no hypertension (OR = 0.89, 95% CI: 0.80–0.99), no diabetes
mellitus (OR = 0.60, 95% CI: 0.54–0.68), no cardiovascular
disease (OR = 0.58, 95% CI: 0.47–0.71) and age group (in years)
(20–44R OR = 1; 45–59R OR = 2.86, 95% CI: 2.52–3.24; 60–
74 R OR = 2.44, 95% CI: 2.13–2.80; $75 R OR = 1.61, 95%
CI: 1.38–1.89). The profile for HDL-c inertia was: female
(OR = 0.68, 95% CI: 0.61–0.76), atrial fibrillation (OR = 1.37,
95% CI: 1.07–1.75), hypertension (OR = 1.22, 95% CI: 1.06–
1.39), diabetes mellitus (OR = 1.82, 95% CI: 1.61–2.06) and
cardiovascular disease (OR = 1.27, 95% CI: 1.04–1.54). Finally,
the variables significantly associated with combined inertia were:
female (OR = 0.46, 95% CI: 0.40–0.54), hypertension (OR = 1.21,
95% CI: 1.03–1.43) and age group (in years) (20–44 R OR = 1;
45–59 R OR = 2.13, 95% CI: 1.76–2.58; 60–74 R OR = 1.53,
95% CI: 1.23–1.91; $75 R OR = 0.97, 95% CI: 0.75–1.24). All
the models were very significant (p,0.001).
Figure 1. Nondyslipidemic patients at primary healthcare centers in a Spanish region. CI, confidence interval; TC, total cholesterol; HDL-c;
high-density lipoprotein cholesterol.
doi:10.1371/journal.pone.0091567.g001
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Discussion
In our study almost four out of every ten patients had diagnostic
inertia of their TC, one in six had diagnostic inertia of their HDL-
c, and one in ten had combined inertia. A search of the literature
showed studies evaluating physician behavior in the diagnosis of
dyslipidemia (Table 1). These papers involve populations that
differ greatly from our study population, in addition to having
different designs, and where this problem does not have this
particular name (inertia) (Table 1). The rate of inertia found in
these studies ranged from 17.1–88.4%. All these papers considered
just TC, so we can only compare them with our results for TC
inertia alone. Our magnitude of TC inertia was below the mean
and median weighted by number of patients (52.7 mean, median
56.7). This indicates that although in our population TC inertia is
a prevalent problem, it is still lower than in other countries.
Factors associated with TC inertia in our study were female; not
having atrial fibrillation, hypertension, diabetes mellitus or
cardiovascular disease; and middle and advanced age. The other
authors (Table 1) reported similar findings, as well as detecting
greater inertia among lower TC levels, certain racial groups, and
in association with social factors, other diseases (liver, dyspnea,
rheumatism and arthritis), unbalanced diet, limited physical
exercise and postgraduate medical training. Differences were also
present in the studies consulted regarding age (Table 1).
Considering that in Spain HDL-c is used to diagnose
dyslipidemia and that we have found no studies evaluating
behavior in the diagnosis of dyslipidemia using HDL-c, we decided
to conduct an analysis in this lipid parameter to quantify the
inertia and its associated factors. The results obtained are of
concern as almost one in every four patients had an abnormal
HDL-c level that was not recognized by the physician (HDL-c
inertia 17.7%, combined inertia 9.6%). But, even more worry-
ingly, the profile of the factors associated with HDL-c inertia
concerned young people, women, and with cardiovascular risk
factors and cardiovascular disease. Furthermore, when abnormal
TC and HDL-c were combined, cardiovascular disease lost its
statistical significance. Regarding age, combined inertia was more
common in middle age than in younger people, like HDL-c
inertia.
When we started the study, we expected to find a lower
magnitude of inertia and that patients with inertia would have a
lower cardiovascular risk. However, the results surprised us
greatly, especially the high prevalence of inertia in all its forms;
and this considering that many of these patients are diagnosed
with other cardiovascular risk factors and they should have their
lipid profile monitored to prevent ischemic heart disease. In
addition, we are concerned that physicians did not assess HDL-c
in patients with a very high cardiovascular risk or in those who had
Table 2. Descriptive analysis of inertia groups for dyslipidemia at primary health care centers in a Spanish region.
Total No inertia TC inertia HDL-c inertia Combined inertia
11,386 3,946 (34.7%) 4,332 (38.0%) 2,013 (17.7%) 1,095 (9.6%)
n(%) n(%) n(%) n(%) n(%)
Variable
Gender:
Male 4,624(40.6) 1,875(47.5) 1,588(36.7) 821(40.8) 340(31.1)
Female 6,762(59.4) 2,071(52.5) 2,744(63.3) 1,192(59.2) 755(68.9)
Atrial fibrillation:
Yes 453(4.0) 179(4.5) 94(2.2) 144(7.2) 36(3.3)
No 10,933(96.0) 3,767(95.5) 4,238(97.8) 1,869(92.8) 1,059(96.7)
Hypertension:
Yes 5,318(46.7) 1,825(46.2) 1,866(43.1) 1,094(54.3) 533(48.7)
No 6,068(53.3) 2,121(53.8) 2,466(56.9) 919(45.7) 562(51.3)
Diabetes mellitus:
Yes 2,804(24.6) 1,007(25.5) 744(17.2) 771(38.3) 282(25.8)
No 8,582(75.4) 2,939(74.5) 3,588(82.8) 1,242(61.7) 813(74.2)
Cardiovascular disease:
Yes 795(7.0) 320(8.1) 167(3.9) 245(12.2) 63(5.8)
No 10,591(93.0) 3,626(91.9) 4,165(96.1) 1,768(87.8) 1,032(94.2)
Age groups (years):
20–44 3,058(26.9) 1,285(32.6) 955(22.0) 541(26.9) 277(25.3)
45–59 2,994(26.3) 782(19.8) 1,434(33.1) 429(21.3) 349(31.9)
60–74 2,967(26.1) 962(24.4) 1,226(28.3) 491(24.4) 288(26.3)
$75 2,367(20.8) 917(23.2) 717(16.6) 552(27.4) 181(16.5)
On-line course by physician:
Yes 1,757(15.4) 576(14.6) 681(15.7) 315(15.6) 185(16.9)
No 9,629(84.6) 3,370(85.4) 3,651(84.3) 1,698(84.4) 910(83.1)
Abbreviations: n(%), absolute frequency(relative frequency); TC, total cholesterol; HDL-c, high density lipoprotein cholesterol.
doi:10.1371/journal.pone.0091567.t002
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a cardiovascular disease. A possible reason that we consider
important and which may justify the conservative attitude of
clinicians in patients with a low HDL-c is the clinical difficulty to
raise these levels, as currently available drugs are not very effective
and lifestyle modifications experience minimum adherence by the
patient [6,32].
Our results suggest that healthcare policies should be active in
the fight against coronary heart disease through the detection and
treatment of its risk factors, like dyslipidemia. However, the
Valencian Community is experiencing an epidemic of obesity
resulting in an increased prevalence of cardiovascular risk factors
[26]. Our findings indicate the need to integrate these healthcare
policies in the health centers, identifying the dyslipidemic patient
early and controlling the situation through drug treatment and
lifestyle changes to reduce the incidence of ischemic heart disease
in the population.
Search Equation
The papers used for comparative purposes were found in
MEDLINE using the following keywords: cholesterol, hypercho-
lesterolemia, cholesterol HDL, cholesterol LDL, hyperlipidemias,
physician, provider, doctor, nurse, professional, routine, style,
manner, action, intervention, practice, experience, conduct,
adherence, guidelines, guide, behavior, behaviour, knowledge,
ignorance and awareness. The filters used were: abstract available,
humans and adult (19+ years).
Study Limitations and Strengths
The source of information corresponds to a unique electronic
record that integrates all the healthcare information from the
health centers. In addition, this paper comprehensively addresses
the novel problem of clinical inertia in dyslipidemia diagnosis.
Furthermore, the sample size is large, minimizing random error
when drawing conclusions from the results obtained in the
population visiting health centers. In addition, the fact that all
the health centers in the Valencian Community participated in
this study and we quantified the problem of inertia in the decisions
of all the members of the primary care teams provides our
conclusions with external validity. This means that our results can
be generalized to populations with a health system similar to ours,
i.e. universal, public, freely available, and without charge to
patients. It would therefore be interesting to conduct similar
studies in other countries with different health policies through
Table 3. Analysis of factors associated with inertia groups for dyslipidemia at primary health care centers in a Spanish region.
Adj. OR Adj. OR Adj. OR
TC inertia p-value HDL-c inertia p-value Combined inertia p-value
(95% CI) (95% CI) (95% CI)
Variable
Gender:
Male 0.64(0.58,0.70) ,0.001 0.68(0.61,0.76) ,0.001 0.46(0.40,0.54) ,0.001
Female*
Atrial fibrillation:
Yes 0.59(0.45,0.77) ,0.001 1.37(1.07,1.75) 0.013 0.84 (0.57,1.24) 0.381
No*
Hypertension:
Yes 0.89(0.80,0.99) 0.029 1.22(1.06,1.39) 0.005 1.21 (1.03,1.43) 0.025
No*
Diabetes mellitus:
Yes 0.60 (0.54,0.68) ,0.001 1.82(1.61,2.06) ,0.001 1.05 (0.89,1.25) 0.534
No*
Cardiovascular disease:
Yes 0.58(0.47,0.71) ,0.001 1.27(1.04,1.54) 0.017 0.80(0.59,1.07) 0.135
No*
Age groups (years):
20–44* ,0.001 0.090 ,0.001
45–59 2.86(2.52,3.24) 1.14 (0.97,1.35) 2.13(1.76,2.58)
60–74 2.44(2.13,2.80) 0.92 (0.77,1.11) 1.53 (1.23,1.91)
$75 1.61 (1.38,1.89) 0.98 (0.82,1.19) 0.97(0.75,1.24)
On-line course by physician:
Yes 1.12(0.99,1.27) 0.078 1.04(0.89,1.21) 0.654 1.18 (0.98,1.42) 0.078
No*
Abbreviations: TC, total cholesterol; HDL-c, high density lipoprotein cholesterol; Adj. OR, Adjusted Odds Ratio; CI, Confidence Interval.
Goodness-of-fit of the inertia models: TC: X2 = 552.7, p,0.001; HDL-c: X2 = 182.9, p,0.001; Combined: X2 = 205.7, p,0.001.
OR adjusted for gender, atrial fibrillation, hypertension, diabetes mellitus, cardiovascular disease, age groups and the on-line course.
*: Reference.
doi:10.1371/journal.pone.0091567.t003
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projects that have large numbers of patients and healthcare
professionals.
The limitations of this study are defined by the design. Since this
was a cross-sectional study, it is not possible to establish a temporal
sequence between the factors and the dependent variable (inertia),
although the status of undiagnosed dyslipidemic patients can be
assessed and their needs determined. These elements are key in
combating unawareness of this problem and prioritizing health-
care planning. The most important bias in this study may be that
which is accepted in this type of study, i.e., selection bias. This bias
is related to the fact that it is the most motivated patients who go to
the health centers. Logically, this cannot be changed as each
person has a different degree of healthcare motivation. However, it
does not affect the aims of this study because we are quantifying
the phenomenon of inertia or a conservative or tolerant attitude by
primary care teams when diagnosing dyslipidemia. Another
weakness of this study concerns under-reporting in the medical
history by healthcare professionals. To minimize this bias, all the
physicians were given the opportunity to participate, voluntarily
and free of charge, in the on-line ESCARVAL course, which
provides training on cardiovascular disease and its risk factors.
Furthermore, as computerized drug prescription is mandatory,
knowing which prescription drugs each patient had been
prescribed enabled us to determine each patient’s disorders, thus
minimizing the under-reporting that is always assumed in these
types of studies. Finally, blood test results (specifically lipids) are
automatically registered in Abucasis, through the electronic
laboratory. A further limitation is not having analyzed other
cardiovascular risk factors, like a family history of cardiovascular
disease, diet, lifestyle, and obesity [6]. This was due to the lack of
these data on the medical records completed by the healthcare
professionals, although these variables would be more beneficial
for the longitudinal ESCARVAL study [33,34]. Finally, we did not
use another parameter for the detection of dyslipidemia (low-
density lipoprotein cholesterol or triglycerides) as in Spain TC and
HDL-c are the only parameters recommended for this process
[8,9].
Conclusion
We think that this study is ideal to quantify the clinical inertia in
the diagnosis of dyslipidemia through computerized systems in the
community. The main point arising from this paper is that we
have to adopt a more proactive attitude towards dyslipidemia.
This attitude should focus on the full diagnosis of dyslipidemia in
clinical practice when a patient meets the criteria, making the
diagnosis as soon as possible. Special emphasis must also be given
to patients with low HDL-c levels and an increased cardiovascular
risk.
Finally, it would be interesting to integrate alarm systems in the
computerized health records system aimed at reducing this
problem, alerting the clinician when a patient has the diagnostic
criteria so that suitable treatment can begin immediately. This
could reduce the inertia and thus the incidence of ischemic heart
disease.
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